Spectral AI Inc. (MDAI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript
Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript
Spectral AI Q2 Earnings Call Highlights
Spectral AI NASDAQ: MDAI said its second-quarter results marked a transition toward commercial operations following the U.S. Food and Drug Administration's De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 million, which does not assume significant revenue from DeepView system sales.
Spectral AI Q1 Earnings Call Highlights
Spectral AI NASDAQ: MDAI said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract.
Spectral AI Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HPL Highlander Partners LP Highlander Partners LP | 900,000 | $2.29M | $1.45M | -$845,789.2 | -36.86% |
 Allison Tronnes Forum Financial Management LP | 60,501 | $125,322.92 | $93,776.55 | -$31,546.37 | -25.17% |
 Nicholas McElroy Philip James Wealth Mangement, LLC | 12,000 | $27,360 | $18,600 | -$8,760 | -32.02% |
Spectral AI Inc. (MDAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Spectral AI Inc. ever had a stock split?
Spectral AI Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Vincent S. Capone CEO | NASDAQ (CM) Exchange | 84757T105 CUSIP |
| US Country | 65 Employees | - Last Dividend | - Last Split | 6 Apr 2021 IPO Date |
Overview
Spectral AI, Inc. is at the forefront of artificial intelligence (AI) innovation, specializing in the field of medical diagnostics. Based in Dallas, Texas, the company's mission focuses on enhancing the speed and accuracy of treatment decisions for patients suffering from burns, diabetic foot ulcers, and similar complex wounds. By integrating AI into the process of medical diagnostics, Spectral AI, Inc. aims to revolutionize the way clinicians assess and approach wound care, ultimately contributing to more effective patient outcomes and the advancement of healthcare technology.
Products and Services
- DeepView:
A cornerstone product of Spectral AI, Inc., DeepView leverages predictive diagnostics technology to provide clinicians with an objective and immediate assessment of a wound's healing potential. This AI-powered device is designed to help healthcare professionals make informed treatment decisions by evaluating numerous factors that influence wound recovery. The goal of DeepView is to improve the quality of wound care treatments, reduce recovery times, and minimize the risk of complications, thereby enhancing the overall patient care experience in cases of burns and diabetic foot ulcers.
